Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: GDRX stock price vs WMT: inconclusive — current versus $3.67 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WMT's multiple
Implied fair value · at GDRX's multiple
Needs GDRX P/E.
Close Dec 31, 2025
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 95% equity / 5% debt · EV / Revenue 1.29x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GoodRx Holdings, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Walmart Inc. · implied price per share
Bear
$26.01
Base
$31.42
Bull
$38.87
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Evolent Health, Inc.
GDRX vs EVH
CVS HEALTH Corp
GDRX vs CVS
Doximity, Inc.
GDRX vs DOCS
Criteo S.A.
GDRX vs CRTO
TARGET CORP
GDRX vs TGT
Costco Wholesale Corporation
GDRX vs COST
Amazon.com, Inc.
GDRX vs AMZN
Walgreens Boots Alliance, Inc.
GDRX vs WBA
DOLLAR GENERAL CORP
GDRX vs DG
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe GDRX can sustain its margin profile and avoid balance sheet deterioration, then the current price looks attractive versus the P/E implied and DCF ranges because the stock is below $3.67 and within a valuation setup that points to upside.
GDRX's current price of $2.66 sits below the P/E implied price of $3.67, suggesting 38.1% upside on that framework. However, the stock is also inside its historical band ($2.39 to $2.93), which tempers the case for a clear re-rating.
Supporting Metrics
